2024/05/03 22:30:00 | |
---|---|
Price | |
77.29 USD | |
Difference | 2.24% (1.69) |
ISIN | US09073M1045 |
Symbol | TECH |
Exchange | Nasdaq |
Currency | USD |
Sector | Other |
Security type | Stock |
Market cap (m) | 11,323 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 75.00 USD (300) |
Ask (Ask size) | 80.20 USD (700) |
Open | 76.89 USD |
High | 77.98 USD |
Low | 76.18 USD |
Close (prev. day) | 75.60 USD |
VWAP | 77.231821 USD |
Volume (pcs) | 1,509,857 |
Trading volume | 116,633,621.63 |
Number of trades | 26,481 |
Last size | - |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/04/26 | Global Equity Ratings | ||
2024/04/03 | Global Equity Ratings | ||
2024/03/13 | Global Equity Ratings | ||
2024/02/22 | Global Equity Ratings | ||
2024/02/14 | Global Equity Ratings |
2024/05/03 22:30:00 | |
---|---|
Price | |
77.29 USD | |
Difference | 2.24% (1.69) |
ISIN | US09073M1045 |
Symbol | TECH |
Exchange | Nasdaq |
Currency | USD |
Sector | Other |
Security type | Stock |
Market cap (m) | 11,323 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 75.00 USD (300) |
Ask (Ask size) | 80.20 USD (700) |
Open | 76.89 USD |
High | 77.98 USD |
Low | 76.18 USD |
Close (prev. day) | 75.60 USD |
VWAP | 77.231821 USD |
Volume (pcs) | 1,509,857 |
Trading volume | 116,633,621.63 |
Number of trades | 26,481 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | +31.62% | -10.11% | -27.50% |
Perf (abs.) | +18.57 | -8.69 | -29.31 |
Beta | 1.36 | 1.01 | 1.15 |
Volatility | 38.50 | 34.21 | 35.54 |
Ø price 5 days | Ø volume 5 days (pcs.) | 70.81 USD (1,963,469) |
Ø price 30 days | Ø volume 30 days (pcs.) | 67.36 USD (1,162,402) |
Ø price 100 days | Ø volume 100 days (pcs.) | 70.96 USD (1,121,505) |
Ø price 250 days | Ø volume 250 days (pcs.) | 72.86 USD (1,033,346) |
YTD High | date | 78.75 USD (2024/03/08) |
YTD Low | date | 61.16 USD (2024/04/18) |
52 Weeks High | date | 89.91 USD (2023/07/21) |
52 Weeks Low | date | 51.79 USD (2023/11/01) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/05/03 | 22:26 | 72.00 EUR | 0.01 | 3 |
Stuttgart | 2024/05/03 | 19:26 | 72.00 EUR | 0.00 | 8 |
Nasdaq | 2024/05/03 | 22:30 | 77.29 USD | 116.63 | 26,481 |
Munich | 2024/05/03 | 08:05 | 70.00 EUR | 0.00 | 2 |
Frankfurt | 2024/05/03 | 21:49 | 72.00 EUR | 0.00 | 3 |
Duesseldorf | 2024/05/03 | 08:11 | 69.50 EUR | 0.00 | 3 |
Berlin | 2024/05/03 | 08:08 | 70.00 EUR | 0.00 | 2 |
BIO-TECHNE CORP. |
- - |
614 McKinley Place North East - 55413-2610 Minneapolis |
Telefon: +1-612-379-8854 |
Fax: +1-612-656-4400 |
E-mail: info@bio-techne.com |
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN. |
Robert Baumgartner | Chairman of Board of Directors |
Alpna Seth | Member of Board of Directors |
Joseph Keegan | Member of Board of Directors |
Randolph Steer | Member of Board of Directors |
Roeland Nusse | Member of Board of Directors |
Rupert Vessey | Member of Board of Directors |
John Higgins | Member of Board of Directors |
Julie Bushman | Member of Board of Directors |
Charles Kummeth | Chairman of Managing Board |
Brenda S. Everson | Member of Executive Committee |
Jim Hippel | Member of Executive Committee |
Kevin Smyth | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer